Call for Expressions of Interest
“Human Brain Project” EU Flagship Programme,
“CDP6 - Modelling allosteric drugs”
Objectives and description
The Human Brain Project of the EU Flagship Programme has published a call for expressions of interest (CEoI) for the “CDP6 - Modelling allosteric drugs”.
The Human Brain Project
(HBP) is an ambitious 10 year research initiative, and part of the EU
flagship program. The HBP is developing an innovative ICT infrastructure
(the HBP Joint Platform), that will help neuroscientists and clinical
researchers integrate data and knowledge about the brain across all
levels of its spatial and temporal organisation. Using detailed digital
representations, reconstructions, and simulations it aims to give tools
to thousands of researchers to advance and accelerate our understanding
of the functioning of the human brain and its diseases.
Under this CEoI,
potential up to two new Partners are expected to group up and submit a
proposal for a challenging project addressing high-level Use Cases for
Modelling of Allosteric Drugs.
Through this Call for Expressions of Interest (CEoI), HBP is looking for new Partners
with a strong track record in Modelling for Drugs, to join the
project's next phase, which will be funded under Horizon 2020.
Innovative
neuromedicine approaches require a detailed understanding of the
molecular and systems-level organization of the human brain, the causes
and mechanisms of diseases, their progression, and the response to
treatments. Because of the high level of complexity of the nervous
system and of intersubject variability in molecular brain organization,
behaviour and disease, addressing these issues for any neuropathology
appears a daunting task. Indeed, for most neurodegenerative diseases,
such as Alzheimer’s and Parkinson’s, there is currently no cure in spite
of the very large investments from academia and industries. The
discovery of new drugs against brain diseases thus has high ethical
priority for the ongoing neuroscience research. HBP offers novel
insights and computational methods to design and in silico select
original classes of drugs.
In particular this CEoI aims to support:
· novel
molecular-simulation based research efforts to accelerate the discovery
of new and more effective treatments of brain diseases;
· use of computational methods to design and in silico select original classes of drugs, based on allosteric mechanisms.
The
selected proposal will become part of the overall HBP planned Work Plan
for SGA2 as new Tasks and will be located in CDP6 in Subproject SP08 (Medical Informatics Platform, MIP).
You can find the HBP Subprojects here: https://www.humanbrainproject.eu/en/collaborate/open-calls/subprojects-ceols/
Eligible participants - Minimum conditions
Organisations, either already part of the HBP Consortium or not, are eligible for funding under this CEoI.
Laboratories
already receiving funding in SGA2 are not allowed to apply for the Call
budget. They can only act as supporting Partners without asking for
additional funding. A laboratory not receiving HBP funding but being
part of a university or organisation that is already a Partner in the
HBP is eligible to participate in the Call.
The
European Commission eligibility and financial rules apply. The new
Partner Organisations must therefore be established in the EU Member States or Horizon 2020 associated countries.
Note:
The addition of new Partners to the Consortium is subject to the
approval of the required FPA and SGA amendments by the HBP Stakeholder
Board and the EC.
Funding conditions and duration
The overall budget for this topic amounts to EUR 225,000 (including 25% indirect costs), for one proposal with two Partners.
Co-funding and/or In-kind contributions not requested, but valued.
The duration of the projects will be 24 months according to the HBP SGA2 period (covering the period from 1 April 2018 to 31 March 2020).
Deadline of proposals' submission
The deadline for the submission of application is 30 September 2017 at 17:00 (GMT+1).
Proposal submission is done exclusively through the online application platform. You can find more information here: http://opencalls.humanbrainproject.eu/forms/15/overview .
Further information
For further assistance related to the call, topics and the content of proposals, please contact: drug-design@opencalls.humanbrainproject.eu .
Please find attached the documents of the call.
More information: http://opencalls.humanbrainproject.eu/forms/15/overview .
Kind regards,
Flora
Flora Stavropoulou
Intern
European Office of Cyprus
Rue du Luxembourg 3, 2nd floor
B-1000, Brussels
Tel/Fax: +32 (0) 2 280 22 85
E-mail: eoc.brussels2@ucy.ac.cy
PLEASE NOTE THAT THE GREEK TRANSLATION IS PROVIDED AT REQUEST OF ANY INTERESTED MEMBER (based on the decision of 22.12.2016 of the EOC Administrative Council).
